期刊文献+

山西省乙型肝炎病毒基因型分布及临床意义研究 被引量:1

Distribution of hepatitis B virus genotypes in Shanxi province and its significance
下载PDF
导出
摘要 目的了解山西省乙型肝炎病毒(HBV)基因型流行病学分布特征,并分析不同基因型与HBV感染谱的相关性。方法用S基因巢式聚合酶链反应-限制片段长度多态性(PCR-RFLP)的基因型分型方法,对44例携带者、70例慢性乙型肝炎、34例慢性重症乙型肝炎、29例肝硬化患者感染的HBV进行分型,并分析了不同感染谱中HBV基因型的分布。结果①177例感染者HBV基因型C型130例(73.5%)和B型43例(24.3%),偶见D型1例(0.6%),未定型3例(1.7%)。②各种乙型肝炎患者的HBV基因型以C型为主,HBV携带者的基因型主要为B基因型。结论山西省乙型肝炎病毒感染者以C型和B型为优势基因型,与我国北方地区HBV基因型分布相似,但亦有少数其他基因型存在。HBV基因型C可能是乙型肝炎病情进展的相关因素。 Objective To understand the distribution of hepatitis B virus genotypes in Shanxi province and to analyse the relationship between HBV genotypes and patients with hepatitis B. Method A nested polymerase chain reaction (nested-PCR) and restriction fragment length polymorphism (RFLP) analysis assay amplifying S-segment sequences of HBV DNA were used for analyzing the distribution of HBV genotypes among 44 HBV carriers,70 patients with chronic hepatitis B, 34 patients with severe chronic hepatitis B and 29 cases liver cirrhosis. Result The following distribution of genotypes was found: HBV genotype C was 73.5%, genotype B was 24.3%, and D-genotype was 0.6%. 3 cases failed to be detected. The genotype C seemed to be most common in patients with chronical active hepatitis and liver cirrhosis.Conclusion The genotypes C and B are two predominant genotypes in Shanxi province, genotype C may be associated with the development of hepatitis.
出处 《中国药物与临床》 CAS 2005年第8期588-590,共3页 Chinese Remedies & Clinics
基金 山西省自然科学基金资助项目(19981079)
关键词 山西 乙型肝炎病毒 基因型 流行病学 肝硬化 聚合酶链反应 Hepatitis B virus Genes Epidemidogic studies
  • 相关文献

参考文献8

二级参考文献22

  • 1病毒性肝炎防治方案(试行)[J].中华传染病杂志,1995,13(4):241-247. 被引量:1767
  • 2Lai CL, Chien RN, Leung NW, et al. A one-year trial to lamivudine for chronic hepatitis B. N Engl J Med, 1998,339:61-68.
  • 3Leung NWY, Lai CL, Chang TT. Three year lamivudine therapy HBV. J Hepatol, 1999,30:59.
  • 4Pichoud C, Berby F, Stuyver L, et al. Persistence of viral replication after anti-HBe seroconversion druing antiviral therapy for chronic hepatitis B. J Hepatol, 2000,32:307-316.
  • 5Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology, 1999,30:1082-1087.
  • 6Lok AS, McMahon BJ. Chronic Hepatitis B. Hepatology, 2001,34:1225-1241.
  • 7Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet, 1997,349:20-22.
  • 8Thibault V, Benhamou Y, Seguret C, et al. Hepatitis B virus(HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus. J Clin Microb, 1999,8:3013-3016.
  • 9Honkoop P, Niesters HG, de Man RA, et al. Lamivudine resistance in immunocompetent chronic hepatitis B Incidence and patterns. J Hepatol, 1997,26:1393-1395.
  • 10Allen MI, Des Lauriers M, Andrews CW, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology, 1998,27:1670-1677.

共引文献240

同被引文献5

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部